Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program-Reference-Cited by-同舟云学术

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program

Published:2015-09-23 Issue:2 Volume:63 Page:276-286
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Attiyeh Edward F.,Maris John M.¹,Lock Richard²,Reynolds C. Patrick³,Kang Min H.³,Carol Hernan²,Gorlick Richard⁴,Kolb E. Anders⁵,Keir Stephen T.⁶,Wu Jianrong⁷,Landesman Yosef⁸,Shacham Sharon⁸,Lyalin Dmitry⁹,Kurmasheva Raushan T.⁹,Houghton Peter J.⁹,Smith Malcolm A.¹⁰

Affiliation:

1. Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute; Philadelphia Pennsylvania

2. Children's Cancer Institute Australia for Medical Research; Randwick New South Wales Australia

3. Texas Tech University Health Sciences Center; Lubbock Texas

4. The Children's Hospital at Montefiore; Bronx New York

5. A.I. duPont Hospital for Children; Wilmington Delaware

6. Duke University Medical Center; Durham North Carolina

7. St. Jude Children's Research Hospital; Memphis Tennessee

8. Karyopharm Therapeutics; Newton Massachusetts

9. Nationwide Children's Hospital; Columbus Ohio

10. Cancer Therapy Evaluation Program, NCI; Bethesda Maryland

Funder

National Cancer Institute

Publisher